Keywords: Isis Pharma, Kynamro, Mipomersen, Cholesterol, Genzyme, Sanofi, R&D pipeline

Isis sees Kynamro delay; adds new drugs to pipeline

Article | 15 December 2011

Print This

California, USA-based Isis Pharmaceuticals (Nasdaq: ISIS) announced yesterday that there will be a slight delay in the submission of the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in